1. Zhou MY, Xie XL, Peng YG, Wu MJ, Deng XZ, Wu Y, et al. From SARS to COVID-19: What we have learned about children infected with COVID-19. Int J Infect Dis 2020;96:710-4. [
DOI:10.1016/j.ijid.2020.04.090] [
PMID] [
PMCID]
2. Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia 2020;34(9):2354-63. [
DOI:10.1038/s41375-020-0959-x] [
PMID] [
PMCID]
3. Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv2019;3(9):1553-62. [
DOI:10.1182/bloodadvances.2018030007] [
PMID] [
PMCID]
4. Jacque N, Leblond V. La leucémie lymphoïde chronique: mise au point [Chronic lymphocytic leukemia]. Presse Med 2019;48(7-8 Pt 1):807-15. [
DOI:10.1016/j.lpm.2019.07.019] [
PMID]
5. Charra B, Ellouadghiri A, Magramane A, Kebbou T, Damaan K, Maghfour A, et al. COVID-19 and fortuitous discovery of chronic lymphocytic leukemia: biological findings and therapeutic challenges. Pan Afr Med J 2020;36:286. [
DOI:10.11604/pamj.2020.36.286.24361] [
PMID] [
PMCID]
6. Melo JV, Catovsky D, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 1986;63(2):377-87. [
DOI:10.1111/j.1365-2141.1986.tb05563.x] [
PMID]
7. Montserrat E. When CLL meets COVID-19. Blood 2020;136(10):1115-6. [
DOI:10.1182/blood.2020008092] [
PMID] [
PMCID]
8. Safarpour D, Srinivasan K, Farooqui M, Roth C, Ghouse M. A Case of COVID-19-Induced Lymphocytosis in a Patient with Treatment-Naive CLL: Should It Be treated? Clin Lymphoma Myeloma Leuk 2020; S2152-650(20):30516-4. [
Pub Med]
9. Wang K, Zuo P, Liu Y, Zhang M, Zhao X, Xie S, et al. Clinical and Laboratory Predictors of In-hospital Mortality in Patients With Coronavirus Disease-2019: A Cohort Study in Wuhan, China. Clin Infect Dis 2020; 71(16):2079-88. [
DOI:10.1093/cid/ciaa538] [
PMID] [
PMCID]
10. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. Ebio Medicine 2020;55:102763.
https://doi.org/10.2139/ssrn.3539682
https://doi.org/10.1101/2020.02.16.20023671 [
DOI:10.1016/j.ebiom.2020.102763]
11. Ali E, Badawi M, Abdelmahmuod E, Kohla S, Yassin MA. Chronic Lymphocytic Leukemia Concomitant with COVID 19: A Case Report. Am J Case Rep 2020; 21:e926062. [
DOI:10.12659/AJCR.926062] [
PMID] [
PMCID]
12. Paneesha S, Pratt G, Parry H, Moss P. Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia. Leuk Res 2020;93:106366. [
DOI:10.1016/j.leukres.2020.106366] [
PMID] [
PMCID]
13. Baumann T, Delgado J, Montserrat E. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report. Leukemia 2020;34(7):1954-6. [
DOI:10.1038/s41375-020-0870-5] [
PMID] [
PMCID]
14. Orsini E, Pasquale A, Maggio R, Calabrese E, Mauro FR, Giammartini E, et al. Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD19 cells in vivo and in vitro. Br J Haematol 2004;125(6):720-8. [
DOI:10.1111/j.1365-2141.2004.04971.x] [
PMID]
15. Di Ciaccio P, McCaughan G, Trotman J, Ho PJ, Cheah CY, Gangatharan S, et al. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Intern Med J 2020;50(6):667-79. [
DOI:10.1111/imj.14859] [
PMID]